Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation
- PMID: 29871978
- DOI: 10.1161/CIRCULATIONAHA.118.034125
Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation
Abstract
Background: Atrial fibrillation is associated with an increased risk of death. High-sensitivity troponin T, growth differentiation factor-15, NT-proBNP (N-terminal pro-B-type natriuretic peptide), and interleukin-6 levels are predictive of cardiovascular events and total cardiovascular death in anticoagulated patients with atrial fibrillation. The prognostic utility of these biomarkers for cause-specific death is unknown.
Methods: The ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) randomized 18 201 patients with atrial fibrillation to apixaban or warfarin. Biomarkers were measured at randomization in 14 798 patients (1.9 years median follow-up). Cox models were used to identify clinical variables and biomarkers independently associated with each specific cause of death.
Results: In total, 1272 patients died: 652 (51%) cardiovascular, 32 (3%) bleeding, and 588 (46%) noncardiovascular/nonbleeding deaths. Among cardiovascular deaths, 255 (39%) were sudden cardiac deaths, 168 (26%) heart failure deaths, and 106 (16%) stroke/systemic embolism deaths. Biomarkers were the strongest predictors of cause-specific death: a doubling of troponin T was most strongly associated with sudden death (hazard ratio [HR], 1.48; P<0.001), NT-proBNP with heart failure death (HR, 1.62; P<0.001), and growth differentiation factor-15 with bleeding death (HR, 1.72; P=0.028). Prior stroke/systemic embolism (HR, 2.58; P>0.001) followed by troponin T (HR, 1.45; P<0.0029) were the most predictive for stroke/ systemic embolism death. Adding all biomarkers to clinical variables improved discrimination for each cause-specific death.
Conclusions: Biomarkers were some of the strongest predictors of cause-specific death and may improve the ability to discriminate among patients' risks for different causes of death. These data suggest a potential role of biomarkers for the identification of patients at risk for different causes of death in patients anticoagulated for atrial fibrillation.
Clinical trial registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00412984.
Keywords: atrial fibrillation; biomarkers; cause of death; prediction.
Similar articles
-
Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.Circulation. 2014 Nov 18;130(21):1847-58. doi: 10.1161/CIRCULATIONAHA.114.011204. Epub 2014 Oct 7. Circulation. 2014. PMID: 25294786 Clinical Trial.
-
N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).J Am Coll Cardiol. 2013 Jun 4;61(22):2274-84. doi: 10.1016/j.jacc.2012.11.082. Epub 2013 Apr 3. J Am Coll Cardiol. 2013. PMID: 23563134 Clinical Trial.
-
High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.J Am Coll Cardiol. 2014 Jan 7-14;63(1):52-61. doi: 10.1016/j.jacc.2013.07.093. Epub 2013 Sep 19. J Am Coll Cardiol. 2014. PMID: 24055845 Clinical Trial.
-
Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.Hosp Pract (1995). 2011 Oct;39(4):7-16. doi: 10.3810/hp.2011.10.918. Hosp Pract (1995). 2011. PMID: 22056819 Review.
-
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Adv Ther. 2012. PMID: 22684583 Review.
Cited by
-
Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease.Cardiovasc Diabetol. 2020 Aug 3;19(1):120. doi: 10.1186/s12933-020-01092-7. Cardiovasc Diabetol. 2020. PMID: 32746821 Free PMC article.
-
Biomarkers, Clinical Variables, and the CHA2DS2-VASc Score to Detect Silent Brain Infarcts in Atrial Fibrillation Patients.J Stroke. 2021 Sep;23(3):449-452. doi: 10.5853/jos.2021.02068. Epub 2021 Sep 30. J Stroke. 2021. PMID: 34649390 Free PMC article. No abstract available.
-
Interleukin-6: Molecular Mechanisms and Therapeutic Perspectives in Atrial Fibrillation.Curr Med Sci. 2025 Apr;45(2):157-168. doi: 10.1007/s11596-025-00021-7. Epub 2025 Mar 4. Curr Med Sci. 2025. PMID: 40035997 Review.
-
GDF-15 as a Biomarker in Cardiovascular Disease.Arq Bras Cardiol. 2021 Mar;116(3):494-500. doi: 10.36660/abc.20200426. Arq Bras Cardiol. 2021. PMID: 33566936 Free PMC article. Review. English, Portuguese.
-
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial.Eur Heart J. 2021 Nov 14;42(43):4455-4464. doi: 10.1093/eurheartj/ehab579. Eur Heart J. 2021. PMID: 34423361 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials